Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Observational
Started
2025-10-15
Last updated
2026-09-04
Condition(s) studied
Breast Cancer - FemaleFertility
Investigational drug(s) / intervention(s)
No intervention (observational study)
No intervention (observational study): This is an observational study. Our study is based on the real-world conditions. We don't have any intervention.
Study summary
This observational study is to learn about the fertility outcomes and decision after breast cancer diagnosis, and the current status of fertility consultation and decision support in young women diagnosed with breast cancer in China.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria:
* Female breast cancer patients, aged 18-40 years at diagnosis.
* Treated at the three participating hospitals between 1 January 2013 and 31 December 2023.
* Complete clinical documentation available in the electronic medical record system.
* Had no child before cancer diagnosis.
Exclusion Criteria:
* Prior reproductive compromise (surgical or diagnostic infertility or pre-existing infertility factors) before cancer diagnosis.
* Presented with de novo stage IV (metastatic) disease.
* Had a history of other malignancies.
* Patients who refuse to participate or cannot be contacted for follow-up.
Primary outcome measure(s)
Childbearing after breast cancer diagnosis — Up to 2026 We followed up with patients who had not given birth before their cancer diagnosis, to establish whether they had given birth by the end of follow-up.
Trial sites (3)
Facility
City
Region
Status
Jilin Cancer Hospital
Changchun
Jilin
Hangzhou First People's Hospital
Hangzhou
Zhejiang
the Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou
Zhejiang
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.